Cara Therapeutics (TVRD) Competitors $33.39 +4.30 (+14.78%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsTrendsBuy This Stock TVRD vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Cara Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity 180 Life Sciences (NASDAQ:ATNFW) and Cara Therapeutics (NASDAQ:TVRD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment. Is ATNFW or TVRD more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Cara Therapeutics N/A N/A N/A Do analysts rate ATNFW or TVRD? Cara Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 91.46%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in ATNFW or TVRD? 44.7% of Cara Therapeutics shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to ATNFW or TVRD? In the previous week, Cara Therapeutics had 4 more articles in the media than 180 Life Sciences. MarketBeat recorded 4 mentions for Cara Therapeutics and 0 mentions for 180 Life Sciences. Cara Therapeutics' average media sentiment score of 0.33 beat 180 Life Sciences' score of 0.00 indicating that Cara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Cara Therapeutics Neutral Which has stronger earnings & valuation, ATNFW or TVRD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACara TherapeuticsN/AN/AN/AN/AN/A Does the MarketBeat Community believe in ATNFW or TVRD? Cara Therapeutics received 1 more outperform votes than 180 Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/ACara TherapeuticsOutperform Votes150.00% Underperform Votes150.00% SummaryCara Therapeutics beats 180 Life Sciences on 8 of the 8 factors compared between the two stocks. Get Cara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricCara TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$105.75M$6.54B$2.04B$8.48BDividend YieldN/A2.64%2.64%4.16%P/E RatioN/A8.8322.6519.90Price / SalesN/A257.0360.47138.25Price / CashN/A65.8551.7234.64Price / BookN/A6.472.064.58Net IncomeN/A$143.70M-$292.00M$248.14M7 Day PerformanceN/A1.27%0.08%0.35%1 Month PerformanceN/A2.40%6.98%9.66%1 Year PerformanceN/A1.09%4.75%8.99% Cara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDCara TherapeuticsN/A$33.39+14.8%$65.00+94.7%N/A$104.01MN/A0.0080News CoverageAnalyst UpgradeGap UpHigh Trading VolumeATNFW180 Life SciencesN/A$0.01+1.4%N/A-21.1%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-83.5%$0.00N/A0.002AIMDWAinosN/A$0.21+48.9%N/AN/A$0.00$106,207.000.0040Gap DownALVOWAlvotechN/A$1.80flatN/A-39.2%$0.00$585.60M0.004Gap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.01-0.8%N/AN/A$0.00N/A0.0015High Trading VolumeBFRIWBiofronteraN/A$0.09-18.1%N/A+72.0%$0.00$38.00M0.0070Gap DownBTMDWbioteN/A$0.02flatN/A-94.5%$0.00$199.38M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.10-4.6%N/A-81.7%$0.00N/A0.008Gap DownCELUWCelularityN/A$0.04-33.3%N/AN/A$0.00$54.22M0.00220Gap Down Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Celularity Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
